Ahrens Brenton Karl 4
4 · Iterum Therapeutics plc · Filed May 29, 2019
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Exercise/Conversion
Restricted Stock Units
2019-05-24−6,154→ 0 total→ Ordinary Shares (6,154 underlying) - Exercise/Conversion
Ordinary Shares
2019-05-24+6,154→ 6,154 total
Holdings
- 1,733,170(indirect: By Canaan X, L.P.)
Ordinary Shares
Footnotes (3)
- [F1]Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.
- [F2]These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The reporting person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The reporting person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
- [F3]On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019.